**Name of Journal:** *World Journal of Methodology*

**Manuscript NO:** 72513

**Manuscript Type:** MINIREVIEWS

**Network meta-analyses: Methodological prerequisites and clinical usefulness**

Christofilos AI *et al*. Clinical relevance of NMAs

Savvas Ilias Christofilos, Konstantinos Tsikopoulos, Alexios Tsikopoulos, Dimitrios Kitridis, Konstantinos Sidiropoulos, Panagiotis Nikolaos Stoikos, Venu Kavarthapu

**Savvas Ilias Christofilos,** Department of Genetics, Evolution, and Environment, University College London, London WC1E 6BT, United Kingdom

**Konstantinos Tsikopoulos,** Department of Pharmacology, School of Medicine, Faculty of Health Sciences Aristotle University of Thessaloniki, Thessaloniki 54124, Greece

**Alexios Tsikopoulos,** Department of Otolaryngology-Head and Neck Surgery, AHEPA University General Hospital, Aristotle University of Thessaloniki, Thessaloniki 57010, Greece

**Dimitrios Kitridis,** Department of Orthopaedics, Aristotle University of Thessaloniki, School of Medicine, George Papanikolaou Hospital Thessaloniki, Thessaloniki 57010, Greece

**Konstantinos Sidiropoulos,** Department of Orthopedics, General Hospital of Serres, Serres 62100, Greece

**Panagiotis Nikolaos Stoikos,** Department of Medicine, University of Thessaly, Larissa 41500, Greece

**Venu Kavarthapu,** Department of Trauma and Orthopaedics, King’s College Hospital NHS Foundation Trust, London SE5 9RS, United Kingdom

**Author contributions:** Karthavapu V and Tsikopoulos K were involved in the conceptualization of the study; Tsikopoulos A and Sidiropoulos K conducted the literature research and extracted relevant information; Tsikopoulos K and Kitridis D assessed the quality of the included studies; Christofilos SI and Stoikos PN were involved in the generation of tables and the writing of the paper; Karthavapu V supervised and revised the paper accordingly; Throughout the study, Christofilos SI was an intern of Professor Maniatis's group at University College London; all authors have read and approved the final manuscript.

**Corresponding author: Savvas Ilias Christofilos, MD, Doctor,** Department of Genetics, Evolution, and Environment, University College London, Gower Street, London WC1E 6BT, United Kingdom. savvaschristofilos@gmail.com

**Received:** October 19, 2021

**Revised:** February 5, 2022

**Accepted:** March 26, 2022

**Published online:** May 20, 2022

**Abstract**

It is an undeniable fact that systematic reviews play a crucial role in informing clinical practice; however, conventional head-to-head meta-analyses do have limitations. In particular, studies can only be compared in a pair-wise fashion, and conclusions can only be drawn in the light of direct evidence. In contrast, network meta-analyses can not only compare multiple interventions but also utilize indirect evidence which increases their precision. On top of that, they can also rank competing interventions. In this mini-review, we have aimed to elaborate on the principles and techniques governing network meta-analyses to achieve a methodologically sound synthesis, thus enabling safe conclusions to be drawn in clinical practice. We have emphasized the prerequisites of a well-conducted Network Meta-Analysis (NMA), the value of selecting appropriate outcomes according to guidelines for transparent reporting, and the clarity achieved *via* sophisticated graphical tools. What is more, we have addressed the importance of incorporating the level of evidence into the results and interpreting the findings according to validated appraisal systems (*i.e*., the Grade of Recommendations, Assessment, Development, and Evaluation system - GRADE). Lastly, we have addressed the possibility of planning future research *via* NMAs. Thus, we can conclude that NMAs could be of great value to clinical practice.

**Key Words:** Network meta-analysis; Quality of evidence; Evidence-based medicine; Systematic reviews

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Christofilos SI, Tsikopoulos K, Tsikopoulos A, Kitridis D, Sidiropoulos K, Stoikos PN, Kavarthapu V. Network meta-analyses: Methodological prerequisites and clinical usefulness. *World J Methodol* 2022; 12(3): 92-98

**URL**: https://www.wjgnet.com/2222-0682/full/v12/i3/92.htm

**DOI**: https://dx.doi.org/10.5662/wjm.v12.i3.92

**Core Tip:** Systematic reviews with or without meta-analyses provide the highest quality of evidence, thus lying on the top of evidence-based medicine hierarchy. However, pair-wise meta-analyses present the inherent limitation of exclusively comparing direct evidence. By contrast, Network Meta-Analyses (NMAs) also consider indirect evidence, thereby offering additional useful information. Conducting an NMA, however, has certain requirements such as assuming that transitivity across the included studies exists. What is more, maintaining sufficient statistical power in the analyses is crucial. In addition, performing head-to-head statistical comparisons before setting up networks of interventions is a prerequisite for a methodologically sound NMA, and selecting not only positive but also negative outcomes is required. Lastly, implementing quality appraisal systems to grade the level of evidence is highly recommended. Should all the above criteria be fulfilled, then accurate clinical conclusions can be drawn from an NMA.

**INTRODUCTION**

Due to the plethora of different interventions for various clinical entities[1] identifying the most efficient and safe treatment is among the prime interests of a researcher[2-4].In the case of conventional meta-analyses, only two interventions can be compared at a time, and only those evaluated in head-to-head trials[5-7]. What is more, intervention effect estimates can only be calculated from direct evidence[2]. In contrast to pair-wise meta-analyses, network meta-analyses (NMA) enable not only simultaneous direct comparisons of multiple interventions but also indirect comparisons provided a common comparator is shared between interventions[2]. This is even possible in the case of two interventions that have never been directly compared[2]. In addition, interventions may also be ranked utilizing the surface under the cumulative ranking (SUCRA) curves, thus allowing for judgments such as which treatment presents the highest probability of being the most effective[2]. It is underlined that identifying more than one highly efficacious treatment in an NMA is a common phenomenon given the subtle differences in treatment rankings of the modalities lying on the top of ranking probabilitiy tables. Overall, incorporating the results from network meta-analyses into clinical practice guidelines could help clinicians select the best available intervention to improve healthcare.

**PREREQUISITES FOR A WELL-CONDUCTED NMA - THE ASSUMPTION OF TRANSITIVITY AND HETEROGENEITY**

For a systematic review of randomized evidence to qualify as a network meta-analysis, the assumption of transitivity must be fulfilled. To elaborate further, transitivity implies that it is possible to conclude hypothetical comparisons through a common comparator[6]. However, this is only possible in the absence of systematic differences between studies[8] with some degree of heterogeneity being permitted[6]. To illustrate further, heterogeneity is defined as a form of inter-study discrepancy due to differences that cause deviations in the observed effects other than sampling error[9]. However, when the discrepancy between studies exceeds that explained by clinical diversity, effects sizes cannot be safely estimated based on direct and indirect evidence and the distribution of effect modifiers needs to be examined[6].

**PREREQUISITES FOR A WELL-CONDUCTED NMA- STATISTICAL POWER**

It is worthy of note that the statistical power of a network of interventions should be sufficient to enable safe clinical conclusions to be drawn. To be more specific, the ratio between the number of included papers relative to the number of the competing interventions should be satisfactory. On top of that, the sample size per intervention arm as depicted by the size of the nodes in a network meta-analysis plot should also be robust enough (Figure 1). Lastly, prospective registration with systems such as the grade of recommendations, assessment, development, and evaluation system (GRADE) is valuable in assessing the heterogeneity and additional characteristics such as publication bias, indirectness, imprecision, the study limitations, and inconsistency[5].

**CONDUCTING PAIR-WISE META-ANALYSIS PRIOR TO NMA**

Of additional note, for a given dataset, researchers must conduct not only NMA but also traditional pair-wise meta-analyses. To be more precise, one can take advantage of early exploration of the results of conventional pair-wise meta-analyses before setting up networks of interventions. Authors should then proceed with the network meta-analysis to take advantage of indirect evidence synthesis for them to supplement their study results.

**PREREQUISITES FOR A WELL-CONDUCTED NMA- SELECTING APPROPRIATE OUTCOMES**

In determining primary and secondary outcomes, both positive and negative results should be considered. Outcomes of primary interest should be prioritized over outcomes of secondary clinical importance to ensure that the findings will be clinically relevant. For instance, laboratory tests are not routinely considered as primary endpoints as they tend to not directly inform decisions. However, they may play an explanatory and/or adjuvant role in explaining the intervention outcome[10].

**FOLLOWING GUIDELINES FOR TRANSPARENT REPORTING**

The PRISMA guidelines represent a checklist of 27 items that may be used when reporting a systematic review of health interventions with or without meta-anlysis[11]. Hutton *et al*[12], in 2015, has expanded the original list by including 5 additional items that apply to network meta-analyses. Firstly, the geometry and summary of the intervention networks have been incorporated in the methods, including a diagrammatic representation and a brief description. What is more, the findings of inconsistency assessment can be included in addition to the presentation of the networks’ structure.

It should be noted that prospective registration (*e.g*. with PROSPERO database) of all NMAs is encouraged. By doing so, transparency is promoted and bias is prevented by avoiding unintended duplicate reviews[13]. It is also highlighted that adherence to a pre-existing protocol plays a crucial role in preventing selective outcome reporting[10,14,15]. In other words, registration of a systematic review in advance of study commencement precludes data manipulation and/or unethical reporting. Last but not least, prospective registration may enable researchers to assess whether the topic they intend to investigate has already been addressed by earlier authors, thus avoiding unnecessary research repetition.

**SOPHISTICATED GRAPHICAL TOOLS IN NMA - DO WE NEED THEM?**

Despite NMAs gaining popularity, a lot of criticism exists given their complex methodology discouraging clinicians from getting involved in this type of research[16]. This is due to the increased level of statistical and computational knowledge required. To tackle this issue, introducing graphical tools into the manuscript results in a significant increase in clarity and reproducibility[16].

What is more, competing interventions can be ranked from the most to the least effective *via* the use of SUCRA curves[2]. On the other hand, league tables enable a structured presentation of the result of each pair of comparisons with its corresponding 95% confidence intervals (Figure 2).

**PUBLICATION BIAS IN NMA AND ITS IMPACT ON CLINICAL ESTIMATES**

It has been evidenced that detection of publication bias (that is typically reporting positive more often than negative results) in NMA is not uncommon. Inevitably, introducing this kind of bias in meta-analysis threatens the validity of the results of the study as an “overly rosy picture” may be painted. To elaborate further, the evaluation of small study effects acts as a proxy for the assessment of publication bias. For the above assessment, a sophisticated statistical tool namely a comparison-adjusted funnel plot can be implemented. Apart from funnel plots, researchers can also employ Egger’s test to statistically evaluate the presence of small-study effects[16-18].

**QUALITY APPRAISAL SYSTEMS AND TRANSITION TO CLINICAL PRACTICE**

The GRADE system features 6 components[5], that are study limitations, heterogeneity, inconsistency, indirectness, imprecision, and publication bias[5,19].The quality of evidence may be high, moderate, low, or very low. As a rule of thumb, randomized trials yield high-quality evidence, whereas observational studies more often than not offer a low quality of evidence with the risk of bias potentially affecting clinical judgment[20].

Potential limitations of randomized trials include failure to conceal allocation, failure to blind, loss to follow-up, and failure to appropriately consider the intention[20]. Guyatt *et al*[20], in 2011, also mentioned terminating a study early for apparent benefit, and selective reporting of outcomes according to the results. The indirectness may be due to patients deviating from those of interest, when the treatments have not been compared in head-to-head trials, and when there are different outcomes from those being expected from the study[21]. Furthermore, the contributions of biological and social factors to the magnitude of effect in the outcomes represents indirectness[21]. On the other hand, inconsistency is defined as a disagreement between direct and indirect evidence in NMA[19]. In addition, Salanti *et al*[19], have suggested the adoption of a quantitative approach to assess the risk of bias.

**INVESTIGATING CLINICAL DIVERSITY IN NMA**

It is an undeniable fact that a great many confounding factors can be encountered in a broad systematic review of randomized trials. Thus, conducting sensitivity analysis to delineate the impact of clinical heterogeneity factors is strongly recommended. For instance, the effect of low-quality trials, variation in intervention characteristics as well as differences due to variable outcome measurement tools needs to be considered in those secondary analyses. From a technical point of view, the researcher needs to improve the trial(s) with the above characteristics from the analysis, repeat the statistical tests and subsequently compare the new results with the findings of the primary analysis[22].

**PLANNING FUTURE RESEARCH WITH NMA- IS IT POSSIBLE?**

Directing the design of future studies based on NMA results appears to be of significant importance as mismanagement of resources can be overcome[23-25]. For a researcher to provide an estimate of whether the results of a subsequent trial are likely to change in the future, an interval plot should be considered. By visually inspecting an interval plot, an investigator can enable predictions on the efficacy of a particular intervention in a future trial[16,26,27].

**IMPROVING INTERPRETATION OF NMA FINDINGS**

To improve interpretability and clarity of the results of an NMA, researchers are encouraged to back-transform their data in a manner that interpretation of their results is improved. For instance, when it comes to Patient-Reported Outcome Measures, investigators can back-transform Standard Mean Differences to Mean Differences and subsequently assess their findings against the established minimal clinically important difference for a particular questionnaire[28].

**CONCLUSION**

Overall, NMAs play a crucial role in the decision-making process. As long as common methodological mistakes are avoided, researchers can produce reliable and accurate clinical conclusions.

**REFERENCES**

1 **Tsikopoulos K**, Vasiliadis HS, Mavridis D. Injection therapies for plantar fasciopathy ('plantar fasciitis'): a systematic review and network meta-analysis of 22 randomised controlled trials. *Br J Sports Med* 2016; **50**: 1367-1375 [PMID: 27143138 DOI: 10.1136/bjsports-2015-095437]

2 **Antoniou SA**, Koelemay M, Antoniou GA, Mavridis D. A Practical Guide for Application of Network Meta-Analysis in Evidence Synthesis. *Eur J Vasc Endovasc Surg* 2019; **58**: 141-144 [PMID: 30528457 DOI: 10.1016/j.ejvs.2018.10.023]

3 **Tsikopoulos K**, Sidiropoulos K, Kitridis D, Cain Atc SM, Metaxiotis D, Ali A. Do External Supports Improve Dynamic Balance in Patients with Chronic Ankle Instability? A Network Meta-analysis. *Clin Orthop Relat Res* 2020; **478**: 359-377 [PMID: 31625960 DOI: 10.1097/CORR.0000000000000946]

4 **Kitridis D**, Tsikopoulos K, Bisbinas I, Papaioannidou P, Givissis P. Efficacy of Pharmacological Therapies for Adhesive Capsulitis of the Shoulder: A Systematic Review and Network Meta-analysis. *Am J Sports Med* 2019; **47**: 3552-3560 [PMID: 30735431 DOI: 10.1177/0363546518823337]

5 **Rouse B**, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. *Intern Emerg Med* 2017; **12**: 103-111 [PMID: 27913917 DOI: 10.1007/s11739-016-1583-7]

6 **Salanti G**. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. *Res Synth Methods* 2012; **3**: 80-97 [PMID: 26062083 DOI: 10.1002/jrsm.1037]

7 **Cipriani A**, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. *Ann Intern Med* 2013; **159**: 130-137 [PMID: 23856683 DOI: 10.7326/0003-4819-159-2-201307160-00008]

8 **Salanti G**, Marinho V, Higgins JP. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. *J Clin Epidemiol* 2009; **62**: 857-864 [PMID: 19157778 DOI: 10.1016/j.jclinepi.2008.10.001]

9 **Lu G,** Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. *J Am Stat Assoc* 2006; **101:** 447-459 [DOI: 10.1198/016214505000001302]

10 **O’Connor D**, Green S, Higgins JPT (editors). Chapter 5: Defining the review question and developing criteria for including studies. In: Higgins JPT, Green S (editors), Cochrane Handbook of Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from: http://www.handbook.cochrane.org

11 **Page MJ**, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021; **372**: n71 [PMID: 33782057 DOI: 10.1136/bmj.n71]

12 **Hutton B**, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015; **162**: 777-784 [PMID: 26030634 DOI: 10.7326/M14-2385]

13 **Stewart L**, Moher D, Shekelle P. Why prospective registration of systematic reviews makes sense. *Syst Rev* 2012; **1**: 7 [PMID: 22588008 DOI: 10.1186/2046-4053-1-7]

14 **Centre for Reviews and Dissemination (CRD)**, University of York:Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care York, UK: Centre for Reviews and Dissemination, University of York 2009. Available from: http://www.york.ac.uk/inst/crd/pdf/Systematic\_Reviews.pdf

15 Finding What Works in Health Care: Standards for Systematic Reviews. Washington (DC): National Academies Press (US); 2011 [PMID: 24983062]

16 **Chaimani A**, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. *PLoS One* 2013; **8**: e76654 [PMID: 24098547 DOI: 10.1371/journal.pone.0076654]

17 **Irwig L**, Macaskill P, Berry G, Glasziou P. Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased. *BMJ* 1998; **316**: 470; author reply 470-470; author reply 471 [PMID: 9492687]

18 **Mavridis D**, Salanti G. Exploring and accounting for publication bias in mental health: a brief overview of methods. *Evid Based Ment Health* 2014; **17**: 11-15 [PMID: 24477532 DOI: 10.1136/eb-2013-101700]

19 **Salanti G**, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. *PLoS One* 2014; **9**: e99682 [PMID: 24992266 DOI: 10.1371/journal.pone.0099682]

20 **Guyatt GH**, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, Falck-Ytter Y, Norris SL, Williams JW Jr, Atkins D, Meerpohl J, Schünemann HJ. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). *J Clin Epidemiol* 2011; **64**: 407-415 [PMID: 21247734 DOI: 10.1016/j.jclinepi.2010.07.017]

21 **Guyatt GH**, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Falck-Ytter Y, Jaeschke R, Vist G, Akl EA, Post PN, Norris S, Meerpohl J, Shukla VK, Nasser M, Schünemann HJ; GRADE Working Group. GRADE guidelines: 8. Rating the quality of evidence--indirectness. *J Clin Epidemiol* 2011; **64**: 1303-1310 [PMID: 21802903 DOI: 10.1016/j.jclinepi.2011.04.014]

22 **Deeks JJ**, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from: http://www.handbook.cochrane.org

23 **Nikolakopoulou A**, Mavridis D, Salanti G. Planning future studies based on the precision of network meta-analysis results. *Stat Med* 2016; **35**: 978-1000 [PMID: 26250759 DOI: 10.1002/sim.6608]

24 **Roloff V**, Higgins JP, Sutton AJ. Planning future studies based on the conditional power of a meta-analysis. *Stat Med* 2013; **32**: 11-24 [PMID: 22786670 DOI: 10.1002/sim.5524]

25 **Fergusson D**, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? *Clin Trials* 2005; **2**: 218-29; discussion 229-32 [PMID: 16279145 DOI: 10.1191/1740774505cn085oa]

26 **Higgins JP**, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. *J R Stat Soc Ser A Stat Soc* 2009; **172**: 137-159 [PMID: 19381330 DOI: 10.1111/j.1467-985X.2008.00552.x]

27 **Riley RD**, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ* 2011; **342**: d549 [PMID: 21310794 DOI: 10.1136/bmj.d549]

28 **Schünemann HJ**, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from: http://www.handbook.cochrane.org

**Footnotes**

**Conflict-of-interest statement:** All authors declare there is no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** October 19, 2021

**First decision:** January 18, 2022

**Article in press:** March 26, 2022

**Specialty type:** Methodology

**Country/Territory of origin:** United Kingdom

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Elfayoumy KN, Egypt; Hasabo EA, Sudan; Yahaya TO, Nigeria **S-Editor:** Liu JH **L-Editor:** A **P-Editor:** Liu JH

**Figure Legends**



**Figure 1 A Network-Meta-Analysis plot example.** Network meta-analysis plot including four competing interventions (*i.e*. A, B, C, and D). The nodes represent the included interventions with their size being proportional to sample size. The thickness of the edges connecting the nodes is reflected in the number of trials included in the given comparison. The edges depicted in green and yellow denote that the involved comparisons are at low and moderate risk of bias, respectively.



**Figure 2 Hypothetical league table demonstrating standardized mean differences, from a network meta-analysis of five competing interventions, that is A-E.** Statistically significant values are depicted in bold.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**